Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade. - Wikidata - awgldk - TriplyDB

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade.

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade.

http://www.wikidata.org/entity/Q37713680

about

Characterization of the Immune Microenvironment in Hepatocellular Carcinoma (HCC).Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.Understanding the Molecular Genetics of Basal Cell Carcinoma.Implications of the tumor immune microenvironment for staging and therapeutics.Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies.A case of metastatic basal cell carcinoma treated with continuous PD-1 inhibitor exposure even after subsequent initiation of radiotherapy and surgery.Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma.

P2860

Q41934377-DA5193E4-5E3E-49E5-ABE2-BA6B77FF09D5 Q42514766-FD1259F5-A5CA-4EE6-BE75-22DC9EEF5350 Q47108777-633A73E1-4AAD-4CF9-B9B8-8A3D7051BADE Q47592007-866D76DA-6DC6-4646-B22E-4EB004D00864 Q52733765-AF711A93-4CFC-4C64-8156-D46D65DE3F54 Q55082713-6943549B-3BBD-402D-9D3D-26379EF0566C Q55358698-DC75BCB8-687E-46C0-B36E-13D0D7071F08

P2860

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade.

http://www.wikidata.org/entity/Q37713680

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 March 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Basal cell carcinoma: PD-L1/PD ...... egression after PD-1 blockade.

@en

Basal cell carcinoma: PD-L1/PD ...... egression after PD-1 blockade.

@nl

type

label

Basal cell carcinoma: PD-L1/PD ...... egression after PD-1 blockade.

@en

Basal cell carcinoma: PD-L1/PD ...... egression after PD-1 blockade.

@nl

prefLabel

Basal cell carcinoma: PD-L1/PD ...... egression after PD-1 blockade.

@en

Basal cell carcinoma: PD-L1/PD ...... egression after PD-1 blockade.

@nl

P1433

Q37713680-455C0EF0-A488-46D3-8809-4E47B6230468

P1476

Q37713680-03F2131D-B329-43B2-AE23-3BA42D18B5C2

P2093

Q37713680-0696F209-9762-4A64-A500-809B12D7C70D

Q37713680-18F58F59-0E78-4725-AD0A-57FEEC62B559

Q37713680-4267284C-0639-437A-9F44-F5CAA870B4DB

Q37713680-462D8200-3A52-4380-A43B-42432E4A88E4

Q37713680-76A434BD-C9B3-4B41-BCD3-498F3DF563A7

Q37713680-7A783B70-8195-4B68-80FA-6459DACF6E5C

Q37713680-DC25A707-4EB7-481E-BFF1-EAD0A7D1070B

Q37713680-F3736EE4-1B16-423B-A96F-91AB50AF40E3

Q37713680-F520EBEC-8AF5-48CB-B5F0-D4C58F65CB66

P2860

Q37713680-0417E654-7CB5-4982-914F-7DB274BED650

Q37713680-0532A30A-2439-4B58-BFC4-4721655CC10A

Q37713680-053F4EDF-F068-4305-8045-2ECD397C97D7

Q37713680-1630ABB1-B28C-4E81-9227-F7A5CC4DBDBD

Q37713680-1947BA3A-49F4-447D-BE6C-32003CBDF9A3

Q37713680-198DCFA1-58D7-4603-A8A7-B5542C2356D2

Q37713680-199E8E5C-CE0A-471F-8808-0267346AE61A

Q37713680-26E85A28-389A-40C8-9691-A2474B40F91C

Q37713680-27D4ACF6-E304-407D-99D1-A4C58D60660F

Q37713680-3C793A1C-0A4D-4148-A4BD-F3120A3ECCA2

P2888

Q37713680-0BD3B311-9A31-4A85-921E-DB085F5636CE

P304

Q37713680-B9753FB2-3441-415D-9849-374941E1A8ED

P31

Q37713680-616979cb-de0f-46bf-bb42-f062f7fcb801

Q37713680-C7B628B0-2F66-41AA-9E79-6E1A83E4C5AD

P356

Q37713680-527B0DEC-2E8E-4526-A408-0370E54D202A

P478

Q37713680-FA5B563A-9837-4D23-861E-A87C72E41300

P577

Q37713680-0F5F09F4-88A9-4C83-AEE9-74C59D1E0E90

P6179

Q37713680-6E522B73-4985-4483-8E54-08882FEE3449

P698

Q37713680-7B9F4F89-B98D-46D6-B0F2-EF343509A9ED

P932

Q37713680-01723B1B-811A-4A12-8204-A715056A558B

P356

S40425-017-0228-3

P1433

Journal for Immunotherapy of Cancer

P1476

Basal cell carcinoma: PD-L1/PD ...... egression after PD-1 blockade.

@en

P2093

Aleksandra Ogurtsova

http://www.w3.org/2001/XMLSchema#string

Evan J Lipson

http://www.w3.org/2001/XMLSchema#string

Haiying Xu

http://www.w3.org/2001/XMLSchema#string

Janis M Taube

http://www.w3.org/2001/XMLSchema#string

Jessica Esandrio

http://www.w3.org/2001/XMLSchema#string

Megan Schollenberger

http://www.w3.org/2001/XMLSchema#string

Mohammed T Lilo

http://www.w3.org/2001/XMLSchema#string

Patricia Brothers

http://www.w3.org/2001/XMLSchema#string

William H Sharfman

http://www.w3.org/2001/XMLSchema#string

P2860

Antagonists of PD-1 and PD-L1 in Cancer Treatment

An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

Immune checkpoint blockade: a common denominator approach to cancer therapy

Signatures of mutational processes in human cancer

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.

Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

P2888

s40425-017-0228-3

P304

23

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S40425-017-0228-3

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1084252940

http://www.w3.org/2001/XMLSchema#string

P698

28344809

http://www.w3.org/2001/XMLSchema#string

P932

5360064

http://www.w3.org/2001/XMLSchema#string